$REFG U.S. Food and Drug Administration’s (FDA

$REFG U.S. Food and Drug Administration’s (FDA) decision to grant orphan drug designation for a cannabis

Medical Cannabis Payment Solutions (OTC Markets: REFG) ( www.refg.co ), issued a statement today supporting the U.S. Food and Drug Administration’s (FDA) decision to grant orphan drug designation for a cannabis extract for use in children with a severe form of epilepsy called Dravet syndrome. The product contains plant-derived Cannabidiol, a non-psychoactive molecule from the cannabis plant.

Jeremy Roberts, CEO of Medical Cannabis Payment Solutions, said: "As a leading proponent of the safe and proper use of legal medical marijuana, it has long been our position that we’re just beginning to see the public health benefits of this amazing herb.”

The company reiterated its position to work with policymakers to form compassionate, data-based regulations.

Mr. Roberts continued, “We’re already working with Utah’s state legislature as they explore similar products to treat epilepsy.”

The company will be meeting with Utah legislators at today’s interim legislative session.